21/12/2022

The investment round is closed!

We are pleased to announce that we have recently closed a 4.8M EUR round of investment. 

We are thrilled to have this new round of funding to further drive our mission of building innovative solutions that enable customers to solve their toughest challenges. 

At Apeiron we are providing efficient metathesis catalysts at scale and unique expertise enabling successful implementation through co-creation projects realized with our clients. Chemical transformations facilitated by our catalysts render the processes economically and environmentally sustainable.

This investment will be used to further expand our production capabilities to meet growing market demand, intensify sales and marketing activities in Europe and US, and create new lab space for continued R&D.


We would like to thank our investors Aper Ventures, ORLEN VC and Adamed Pharma for their continued support and belief in our mission.

We look forward to working together to create solutions that will make a lasting impact.

 

If you would like to read more click here